LATESTSEARCH ⌕
NASDAQ / LIVE COMPANY INTELLIGENCE

Dyadic International, Inc.

Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.

TICKERDYAI
CORENasdaq-listed company
WATCHEarnings + filings + operating news
STATUSContinuously updated
LIVE / DYAI COVERAGE

What’s moving Dyadic International, Inc. now

Current reporting with the operating signal separated from the noise.

01
Dyadic International, Inc.: Dyadic Announces Continued Listing on the Nasdaq Capital Market

Dyadic International, Inc.: Dyadic Announces Continued Listing on the Nasdaq Capital Market

The story matters when it changes Dyadic International, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
02
Dyadic International, Inc.: Dyadic Applied BioSolutions and Inzymes ApS Announce Planned 2026 Commercialization of Non-Animal Dairy Enzyme Following Achievement of Development ...

Dyadic International, Inc.: Dyadic Applied BioSolutions and Inzymes ApS Announce Planned 2026 Commercialization of Non-Animal Dairy Enzyme Following Achievement of Development ...

The development tests whether Dyadic International, Inc. can turn product investment into adoption, revenue and durable advantage.

Watch next: confirmation in a company filing, official release or regulator record.
03
Dyadic International, Inc. (DYAI) Q3 2025 Earnings Call Transcript

Dyadic International, Inc. (DYAI) Q3 2025 Earnings Call Transcript

Investors are testing whether Dyadic International, Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
04
Dyadic International, Inc. Announces Leadership Change and Strategic Shift Towards Ancillary Protein Market

Dyadic International, Inc. Announces Leadership Change and Strategic Shift Towards Ancillary Protein Market

The story matters when it changes Dyadic International, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
05
Dyadic International, Inc. Advances Alternative Proteins Business and Vaccine Development Ahead of J.P. Morgan Healthcare Conference

Dyadic International, Inc. Advances Alternative Proteins Business and Vaccine Development Ahead of J.P. Morgan Healthcare Conference

The story matters when it changes Dyadic International, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
06
Dyadic International, Inc. and Proliant Health and Biologicals announce Recombinant Albumin Development and Commercialization Partnership

Dyadic International, Inc. and Proliant Health and Biologicals announce Recombinant Albumin Development and Commercialization Partnership

The story matters when it changes Dyadic International, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
PRIMARY DOCUMENTS / SEC EDGAR

Latest DYAI filings.

Investor-relevant reports are shown first, followed by the company’s other recent official submissions.

10-QQuarterly financial reportFiled 2026-05-13 · Period 2026-03-31SEC ↗10-QQuarterly financial reportFiled 2025-11-12 · Period 2025-09-30SEC ↗10-K/AAnnual financial reportFiled 2026-04-30 · Period 2025-12-31SEC ↗8-KMaterial company eventFiled 2026-07-24 · Period 2026-07-24SEC ↗8-KMaterial company eventFiled 2026-06-22 · Period 2026-06-18SEC ↗8-KMaterial company eventFiled 2026-06-18 · Period 2026-06-18SEC ↗DEF 14AProxy and shareholder meetingFiled 2026-05-12 · Period 2026-05-12SEC ↗4Official SEC filingFiled 2026-07-24 · Period 2026-07-22SEC ↗
EARNINGS / QUARTERLY TRACKER

Dyadic International, Inc., quarter by quarter.

Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.